DK1694354T3 - Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin - Google Patents

Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin

Info

Publication number
DK1694354T3
DK1694354T3 DK04803341T DK04803341T DK1694354T3 DK 1694354 T3 DK1694354 T3 DK 1694354T3 DK 04803341 T DK04803341 T DK 04803341T DK 04803341 T DK04803341 T DK 04803341T DK 1694354 T3 DK1694354 T3 DK 1694354T3
Authority
DK
Denmark
Prior art keywords
preventing
neurturin
treating diabetes
diabetes
administering
Prior art date
Application number
DK04803341T
Other languages
English (en)
Inventor
Matthias Austen
Ulrike Burk
Original Assignee
Develogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag filed Critical Develogen Ag
Application granted granted Critical
Publication of DK1694354T3 publication Critical patent/DK1694354T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
DK04803341T 2003-11-27 2004-11-29 Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin DK1694354T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03027383 2003-11-27
PCT/EP2004/013534 WO2005051415A1 (en) 2003-11-27 2004-11-29 Method for preventing and treating diabetes using neurturin

Publications (1)

Publication Number Publication Date
DK1694354T3 true DK1694354T3 (da) 2009-10-26

Family

ID=34626383

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04803341T DK1694354T3 (da) 2003-11-27 2004-11-29 Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin

Country Status (9)

Country Link
US (4) US20080241106A1 (da)
EP (1) EP1694354B1 (da)
JP (5) JP4838724B2 (da)
AT (1) ATE435026T1 (da)
DE (1) DE602004021847D1 (da)
DK (1) DK1694354T3 (da)
ES (1) ES2329583T3 (da)
PL (1) PL1694354T3 (da)
WO (1) WO2005051415A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
ATE435026T1 (de) * 2003-11-27 2009-07-15 Develogen Ag Verfahren zur prävention und behandlung von diabetes mit neurturin
EP1872790A1 (en) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
US8637459B2 (en) * 2006-11-08 2014-01-28 Emory University Enhancing a population of insulin releasing cells using GFR-A1 agonists
MX2010004899A (es) * 2007-11-05 2010-09-07 Develogen Ag Conjugados de neurturina novedosos para uso farmaceutico.
JP2011057674A (ja) 2009-09-11 2011-03-24 Omnica Gmbh コエンザイムｑ−１０と抗酸化剤とを含む組成物
US9127083B2 (en) 2009-10-30 2015-09-08 Ntf Therapeutics, Inc. Neurturin molecules
EP2774935B8 (en) * 2009-10-30 2017-06-21 NTF Therapeutics, Inc. Improved neurturin molecules
US8445432B2 (en) 2009-10-30 2013-05-21 Ntf Therapeutics Inc Neurturin molecules
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
WO2012150707A1 (ja) * 2011-05-02 2012-11-08 国立大学法人熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法
WO2013063389A2 (en) * 2011-10-26 2013-05-02 University Of Louisville Research Foundation, Inc. Methods and compositions for treating diabetes and other degenerative neuroendocrine diseases or disorders
US9821026B2 (en) * 2012-06-28 2017-11-21 Instituto De Medicina Molecular Use of RET agonist molecules for haematopoietic stem cell expansion protocols and transplantation therapy and a RET agonist kit
AU2014225307A1 (en) * 2013-03-08 2015-09-24 The Curators Of The University Of Missouri Methods and compositions for the treatment and/or prevention of type 1 diabetes
EA201791225A1 (ru) 2014-12-03 2017-12-29 Велисепт Терапьютикс, Инк. Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
FI3365321T3 (fi) 2015-10-23 2024-01-02 B3Ar Therapeutics Inc Solabegron-Zwitterioni ja sen käyttöjä
JP6960106B2 (ja) * 2018-01-17 2021-11-05 Toto株式会社 浴槽用枕
EP3976096A4 (en) * 2019-05-30 2023-11-08 Immunolux International Corp. USE OF POXVIRUS WITH AUTOLOGOUS INDUCED PLURIPOTENT STEM CELLS FOR VACCINATION AND DISEASE THERAPY
EP4284440A1 (en) * 2021-01-30 2023-12-06 Universitat Autònoma De Barcelona Gene therapy for monogenic diabetes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743628B1 (en) 1995-08-28 2004-06-01 Washington University Method of cell culture using neurturin
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
EP1010432A4 (en) * 1997-01-23 2004-03-10 Sumitomo Pharma REMEDIES FOR DIABETES
ATE312915T1 (de) * 1997-02-18 2005-12-15 Genentech Inc Neurturin-rezeptor
US6043221A (en) 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
WO2000017360A1 (en) 1998-09-22 2000-03-30 University Of Maryland, Baltimore Cystine knot growth factor mutants
WO2000018922A2 (en) 1998-10-01 2000-04-06 Incyte Genomics, Inc. Human carbohydrate-associated proteins
AU1997501A (en) 1999-10-29 2001-05-08 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of GDNF for treating corneal defects
WO2001057251A2 (en) 2000-02-04 2001-08-09 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
JP2004527249A (ja) * 2001-04-19 2004-09-09 デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング 幹細胞をインスリン産生細胞に分化する方法
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
EP2275118A3 (en) 2002-05-29 2011-10-19 DeveloGen Aktiengesellschaft Pancreas-specific proteins
WO2004093804A2 (en) 2003-04-18 2004-11-04 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
ATE435026T1 (de) * 2003-11-27 2009-07-15 Develogen Ag Verfahren zur prävention und behandlung von diabetes mit neurturin
EP1872790A1 (en) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
MX2010004899A (es) 2007-11-05 2010-09-07 Develogen Ag Conjugados de neurturina novedosos para uso farmaceutico.

Also Published As

Publication number Publication date
EP1694354B1 (en) 2009-07-01
ES2329583T3 (es) 2009-11-27
JP5647577B2 (ja) 2015-01-07
ATE435026T1 (de) 2009-07-15
JP2016000759A (ja) 2016-01-07
JP4838724B2 (ja) 2011-12-14
JP2007512290A (ja) 2007-05-17
JP2012001546A (ja) 2012-01-05
US8399408B2 (en) 2013-03-19
US20080241106A1 (en) 2008-10-02
DE602004021847D1 (de) 2009-08-13
JP2011251986A (ja) 2011-12-15
JP2014074066A (ja) 2014-04-24
WO2005051415A1 (en) 2005-06-09
US20140274897A1 (en) 2014-09-18
EP1694354A1 (en) 2006-08-30
US20110256113A1 (en) 2011-10-20
US20130150293A1 (en) 2013-06-13
US8772233B2 (en) 2014-07-08
PL1694354T3 (pl) 2009-12-31

Similar Documents

Publication Publication Date Title
DK1694354T3 (da) Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin
DK1427758T3 (da) Præparater og fremgangsmåder til behandling af diabetes
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2006073973A3 (en) Novel benzylamine derivatives as cetp inhibitors
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20063196L (no) Nye fusjonerte pyrrolokarbazoler
DK2527315T3 (da) Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom
DK1505990T3 (da) Fremgangsmåder til behandling af hepatitis
IS8274A (is) Adamantýlglýsín-grunnaðir tálmar dípeptídýl peptídasa IV og aðferðir
WO2005086661A3 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
RS20060320A (en) Substituted indazole-o-glucosides
DK1971601T3 (da) N4-phenyl-quinazolin-4-aminderivater og beslægtede forbindelser som ERBB Type 1-receptortyrosinkinase-inhibitorer til behandling af hyperproliferative sygdomme
WO2003096983A3 (en) Method of treating dyslipidemic disorders
EA200600203A1 (ru) Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
SG130189A1 (en) Substituted indole-o-glucosides
DE602005017895D1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
TW200738270A (en) Method of treating depression using a TNFα antibody
WO2005046603A3 (en) Pyridine compounds
DK1809663T3 (da) Fremgangsmåde til oprensning af FSH
NO20072199L (no) Trombopoietinaktivitetsmodulerende forbindelser og fremgangsmater
DK1143955T3 (da) En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2006042745A3 (de) Chemisch modifizierte iapp - peptidanaloga
NO20052655L (no) Sammensmeltede heterocykliske forbindelser